Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8895432 | 1.00 | GRIK1 (0.50) | GRIK1SIGMAR1MAOAANPEPERAP1 | |
| SCHEMBL8896138 | 1.00 | GRIK1 (0.50) | GRIK1SIGMAR1MAOAANPEPERAP1 | |
| SCHEMBL27527666 | 0.94 | S1PR2 (0.50) | GRIK1SIGMAR1MAOAANPEPERAP1 | |
| SCHEMBL1029067 | 0.88 | ANPEP (0.52) | GRIK1ANPEPERAP1ERAP2HTR2A | |
| SCHEMBL8007380 | 0.88 | ANPEP (0.52) | GRIK1ANPEPERAP1ERAP2HTR2A | |
| SCHEMBL3391050 | 0.88 | ANPEP (0.52) | GRIK1ANPEPERAP1ERAP2HTR2A | |
| SCHEMBL1274321 | 0.81 | GRIK1 (0.50) | GRIK1SIGMAR1MAOAANPEPERAP1 | |
| SCHEMBL9819985 | 0.80 | SIGMAR1 (0.48) | GRIK1SIGMAR1MAOAKCNH2 | |
| SCHEMBL3266047 | 0.77 | S1PR2 (0.59) | GRIK1SIGMAR1MAOAANPEPERAP1 | |
| SCHEMBL5789705 | 0.77 | MAOA (0.54) | GRIK1SIGMAR1MAOAANPEPERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612239-B2 | Method for asymmetric alkynylation of alpha-imino esters | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2009-11-03 | — | — | US | disclosed |
| US-20080183010-A1 | Method For Asymmetric Alkynylation Of Al Pha-Imino Esters | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080183010-A1 | Method For Asymmetric Alkynylation Of Al Pha-Imino Esters | ALKBH3, CYP8B1, ALKBH1 | GRIK1 3934/4885SIGMAR1 1159/4885MAOA 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.